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Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative
disease associated with aging; it affects about 5–7% of individuals
over 65 years thus representing a major public health problem. An
effective pharmacological treatment for AD has not yet been found
and progress in deciphering the biological mechanisms of AD
pathogenesis can provide significant clues to develop new pharma-
cological strategies against such severe pathology. Accumulation
of amyloid- peptide (A) aggregates in the central nervous sys-
tem (CNS) is an inherent feature of AD (reviewed in 1). A40 and
A42 peptides arise from intracellular processing of APP carried
out by BACE and -secretase in the amyloidogenic pathway [1–3].
Cholesterol appears predominantly synthesized de novo in 
the CNS, where it enhances the production of pre-synaptic 
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Abstract
The role of brain cholesterol in Alzheimer’s disease (AD) is currently a matter of debate. Experimental evidence suggests that reducing
circulating and brain cholesterol protects against AD, however recent data indicate that low membrane cholesterol results in neurode-
generation and that the cholesterol synthesis catalyst seladin-1 is down-regulated in AD-affected brain regions. We previously reported
a significant correlation between resistance to amyloid toxicity and content of membrane cholesterol in differing cultured cell types. Here
we provide evidence that A42 pre-fibrillar aggregates accumulate more slowly and in reduced amount at the plasma membrane of
human SH-SY5Y neuroblastoma cells overexpressing seladin-1 or treated with PEG-cholesterol than at the membrane of control cells.
The accumulation was significantly increased in cholesterol-depleted cells following treatment with the specific seladin-1 inhibitor 5,22E-
cholestadien-3-ol or with methyl--cyclodextrin. The resistance to amyloid toxicity and the early cytosolic Ca2+ rise following exposure
to A42 aggregates were increased and prevented, respectively, by increasing membrane cholesterol whereas the opposite effects were
found in cholesterol-depleted cells. These results suggest that seladin-1-dependent cholesterol synthesis reduces membrane-aggregate
interaction and cell damage associated to amyloid-induced imbalance of cytosolic Ca2+. Our findings extend recently reported data indi-
cating that seladin-1 overexpression directly enhances the resistance to A toxicity featuring seladin-1/DHCR 24 as a possible new sus-
ceptibility gene for sporadic AD.
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components and synaptic vesicles, whereas statins block dendrite
outgrowth and axonal branching [4]. The role of cholesterol in AD
pathogenesis is still controversial [5]. High cholesterol levels as
risk factor for AD were first proposed in the early 1990s and since
then considerable biochemical and clinical research has claimed
the existence of a link between cholesterol, statin therapy and AD
development [6–10]. On the other hand, it is known that
hydrophilic statins do not cross the blood brain barrier and that
brain cholesterol progressively reduces with increasing age (the
main risk factor for sporadic AD), such decrease appearing 
considerably accelerated in AD people [11]. Presently, the ques-
tion of whether statins can lower the incident rate of AD remains
unresolved [12]. Recent findings suggest that the proteolytic
machinery required for A generation is located within lipid rafts or
detergent-resistant membranes (DRMs) that are discrete choles-
terol-rich microdomains of the cell membrane involved in a wide
range of key biological processes [13, 14].
A key role of membrane cholesterol as a modulator of A pep-
tide production and clearance [15] as well as aggregation and neu-
rotoxicity [16–19] has recently been described. In the hippocam-
pus of healthy humans and transgenic mice expressing moderate
levels of human APP only a small pool of endogenous APP and 
site APP cleaving Enzyme or -secretase (BACE) colocalize in the
same membrane environment. An increased APP/BACE colocal-
ization, likely caused by lipid raft disorganization, is found in hip-
pocampal membranes from AD patients or in rodent hippocampal
neurons with a moderate reduction of membrane cholesterol and
is associated with elevated A production. DRMs disruption also
results in reduced activity of the A-degrading enzyme plasmin
because of decreased plasminogen binding to the plasma mem-
brane [20–22]. Accordingly, rodents treated with lovastatin, the
most permeable statin to the blood brain barrier, display increased
A production and senile plaque deposition [23]. Altogether, these
data support a link between AD pathogenesis and loss of brain 
cholesterol suggesting that a fine modulation of the levels of this
membrane sterol plays a crucial role in neuronal viability.
Seladin-1, a recently characterized gene, is down-regulated in
neurons of AD-affected brain areas [24]. Seladin-1 overexpression
appears to protect neuroglioma H4 cells against A-mediated tox-
icity by reducing oxidative stress and caspase 3 activity [24].
Remarkably, the gene product is identical to DHCR24, the enzyme
that catalyses the last step of cholesterol biosynthesis by reducing
the 24 double bond of desmosterol. A mutation of this gene is
associated with desmosterolosis, a severe disease which affects,
among others, the nervous system [25]. We have recently shown
that seladin-1 expression in human mesenchymal stem cells
(hMSC) is abundant, but decreases dramatically upon differentia-
tion into a neuronal phenotype (hMSC-n) with concomitant reduc-
tion of the total content of cholesterol [26]. This finding provides
a new experimental approach to study the role of membrane cho-
lesterol in the early events associated with neurodegeneration. Our
recent studies demonstrate an hormonal regulation of seladin-1
expression [27, 28]; oestrogens and selective estrogen receptor
modulators (SERMS) up-regulate seladin-1 in a long-term neu-
roblast cell culture from human foetal olfactory epithelium. This
effect results in higher resistance to A-induced toxicity and
oxidative stress, featuring seladin-1 as a mediator of the neuro-
protective effect of oestrogens [28]. A recent investigation on the
involvement of seladin-1 in APP processing in mouse brains and
in cultured neuroblastoma cells suggests that seladin-1-depend-
ent cholesterol synthesis is involved in controlling APP location
and processing as well as A levels [29]. 
Whether seladin-1 protects against A by merely controlling
APP processing or also by directly enhancing cell resistance to A
cytotoxicity remains to be elucidated. It has been proposed that
A acts by forming specific channels in the plasma membranes of
the exposed cells allowing a toxic flux of Ca2+ ions to penetrate
inside them [30]. It has also been shown that enriching with cho-
lesterol the plasma membranes of PC12 and GT1-7 cells modifies
membrane fluidity preventing A incorporation into, and perme-
abilization of, the cell membrane [16, 17, 31]. We have previously
shown that differing cultured cell types exhibit different resistance
to amyloid toxicity and that the latter significantly correlates,
among others, to the content of membrane cholesterol [32].
Accordingly, in the present study we investigated the relationship
between cell resistance to amyloid toxicity, content of membrane
cholesterol and seladin-1 levels by modulating the expression or
the enzymatic activity of the latter in SH-SY5Y neuroblastoma
cells. We provide evidence that in this neurotypic cell model (i)
seladin-1 plays a key role as a modulator of the content of mem-
brane cholesterol; (ii) high membrane cholesterol resulting from
seladin-1 overexpression or treatment with PEG-cholesterol sig-
nificantly protects cells against A42 aggregate toxicity; (iii) low
membrane cholesterol in cells treated with the seladin-1 inhibitor
22 or with -CD results in increased cell vulnerability to A42
aggregates; (iv) the different viability of cholesterol-enriched or
cholesterol-depleted cells matches a reduced or increased interac-
tion of the A42 oligomers with the cell membrane, respectively;
(v) the levels of intracellular free Ca2+ results significantly reduced
or increased in cholesterol-enriched or cholesterol-depleted cells,
respectively. Our results support the idea that seladin-1 protects
cells against amyloid toxicity not only by controlling DRMs
dynamics, APP processing and A production, as previously
shown [29], but also by directly enhancing cell resistance to A
toxicity. Both these mechanisms establish a link between seladin-
1 down-regulation and AD pathogenesis featuring seladin-1 as a
susceptibility gene candidate for sporadic AD and its pharmaco-
logical modulation as a possible novel approach in AD therapy.
Materials and methods
Materials and cell culture
All reagents were of analytical grade or the highest purity available.
Cholesterol, Bradford reagent and BSTFA, Congo Red, PEG-cholesterol, -
CD and other chemicals were from Sigma, unless otherwise stated.
Stigmasterol and 22 were from Steraloids Inc. (Newport, RI, USA).
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Wheat germ agglutinin-conjugated fluorescein, Fluo3-AM, Calcein-AM and
pluronic acid F127 were purchased from Molecular Probes (Eugene, OR,
USA). Hoechst 33342 was from Immunochemistry Technologies, LLC
(Bloomington, MN, USA). Lyophilized A42 and A40 peptides, as trifluo-
roacetate salts (Bachem, Bübendorf, Switzerland), were stored and recon-
stituted as previously reported [33]. Lyophilized amylin 1-37 (Sigma,
Milan, Italy) was stored and processed as previously reported [34]. Human
SH-SY5Y neuroblastoma cells were obtained from A.T.C.C. (Manassas, VA)
and were cultured in Dulbecco’s modified eagle’s medium (DMEM)/F-12
Ham with 25 mM N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid)
(HEPES) and NaHCO3 (1:1) supplemented with 10% foetal bovine serum
(FBS), 1.0% glutamine and 1.0% antibiotics from Sigma (Milan, Italy) in a
5.0% CO2 humidified atmosphere at 37°C in tissue plastic-ware from PBI
international (Milan, Italy).
Seladin-1 up regulation by transient transfection
and selective inhibition by 22
Cells were transiently transfected with a construct, kindly provided by Dr.
I. Greeve [24], containing the seladin-1 open reading frame cloned in
pEGFP-N1 vector (Clontech) using Lipofectamine 2000 (Invitrogen
Carlsbad, CA, USA) on cells plated at 90% confluence in DMEM/F12 sup-
plemented with 10% FBS without antibiotics. 48 hrs after transfection the
cells were used for the A42 toxicity experiments. Selective inhibition of
seladin-1/DHCR24 by 22 was carried out by cell exposure to 10 µM 22
in ethanol (final ethanol concentration 0.2%) for 48 hrs replacing the
medium after 24 hrs. 
Membrane cholesterol enrichment with 
PEG-cholesterol or depletion with 
methyl--cyclodextrin
The increase of membrane cholesterol content was achieved by supple-
menting cell culture media with 0.1 mM PEG-cholesterol for 1 hr at 37°C,
before cell exposure to the aggregates, as previously described [34].
Membrane cholesterol depletion was performed by incubating the cells
with 1.0 mM -CD for 30 min. at 37°C in the presence of 1.0 % FBS. 
Cholesterol and desmosterol measurements
The amount of cholesterol in the cells was determined by gas chromatog-
raphy-mass spectrometry (GC-MS) as previously described with minor
modifications [26]. Briefly, cells were maintained in medium without FBS
for at least 6 hrs, then harvested in Phosphate Buffered Saline (PBS), pel-
letted and frozen in liquid nitrogen for storage at –80°C. Cell pellets were
homogenized in PBS containing 9.0% sucrose with three short pulses of a
polytron homogenizer (Ultraturrax T8, IKA LABORTECHNIK, Germany) in
ice. The samples were centrifuged at 700x g for 10 min. at 4°C and the
supernatant was considered as total extract. A further centrifugation of 
the supernatant was performed at 110,000x g for 1 hr at 4°C to pellet the
membrane fraction. Aliquots corresponding to 5.0g of protein, as deter-
mined by the method of Bradford [35], were used for cholesterol determi-
nation in total extract or membrane fraction. After the addition of stigmas-
terol (1000 ng) as an internal standard, sterols were extracted, derivatized
and automatically injected in a Hewlett-Packard GC-MS system. A six-point
calibration curve in the 50-2000 ng cholesterol range was used for choles-
terol quantification. The peak area ratios (PAR) were calculated using the
signals at 458 m/z and 484 m/z for cholesterol and stigmasterol, respec-
tively. Desmosterol was quantified by using the same procedure of choles-
terol on sample aliquots containing 70 µg of protein. The PAR were calcu-
lated using the signal at 343 m/z. 
Aggregate binding to the cell 
membrane and plasmin activity 
The interaction of A42 aggregates with plasma membranes was moni-
tored in neuroblastoma cells seeded on glass coverslips by confocal scan-
ning microscopy as previously described [33]. Briefly, after treatment with
1.0 µM A42 pre-fibrillar aggregates for 10, 20, 30 and 60 min., the cells
were counterstained with fluorescein-conjugated wheat germ agglutinin
(50 µg/ml) for 10 min. to detect plasma membrane profiles and fixed in
2.0% buffered paraformaldehyde for 10 min. at room temperature. After
plasma membrane permeabilization with a 3.0% glycerol solution, the cov-
erslips were incubated for 60 min. with 1:1000 diluted mouse monoclonal
anti-A antibodies 6E10 (Signet, DBA, Italy) and then with 1:1000 diluted
Texas Red-conjugated anti-mouse secondary antibodies (Vector
Laboratories, DBA, Italy) for 90 min. Cell fluorescence was analysed by a
confocal Bio-Rad MCR 1024 ES scanning microscope (Hercules, CA, USA)
equipped with a Nikon Plan Apo 60 oil immersion objective and a kryp-
ton/argon laser source (15 mW) using two emission lines at 568 nm and
488 nm for Texas Red and fluorescein excitation, respectively.
Fluorescence was achieved by Java image processing program (ImageJ)
and expressed as fractional change above the resting baseline, F/F, where
F is the average baseline fluorescence before the application of peptide and
F represents the fluorescence changes over the baseline. The quantitation
of aggregate adsorption to the cell surface was performed in neuroblas-
toma cells using the specific Congo Red dye as previously described [32].
Briefly, the same number of cells, representative of differing cholesterol
enrichment or depletion conditions, was treated for 0, 5, 10, 20, 30, 60
min. with 1.0 µM A42 aggregates in a 96-well plate and then washed
twice with PBS. The residual aggregate-cell complexes were stained with
100 µL of 1.0 µM Congo Red in PBS for 20 min. at 37°C and measured
photometrically at 550 nm with an ELISA plate reader according to Datki
[36]. Congo Red values are reported as percent increases with respect to
untreated cells (assumed as 100%). Endogenous plasmin enzymatic activ-
ity was assayed using the chromogenic substrate S-2251 (Chromogenix-
Instrumentation Laboratory, Milan, Italy), according to Crameri with minor
modification [29]. Briefly, cell pellets were homogenized in Hank’s bal-
anced saline solution (HBSS) (Sigma) with three short pulses of the ultra-
turrax T8 in ice, then 200 µg of the total cell lysate was placed in a 96-well
plate in the presence of 2.0 mM chromogenic peptide. Absorbance was
measured at 37°C and 405 nm every 5 min. for 60 min. on a Victor3 multi-
label reader (Perkin Elmer, Milan, Italy).
Confocal analysis of cytosolic Ca2+ transients
The modifications of the intracellular free Ca2+ concentration in SH-SY5Y
cells were monitored in cells plated on glass coverslips and incubated at
room temperature for 10 min. in serum-free DMEM containing 0.1%
bovine serum albumin (BSA), 10 µM Fluo3-AM as fluorescent calcium indi-
cator, 0.1% dimethylsulfoxide (DMSO) and Pluronic acid F-127 (0.01%
w/v) as previously reported [32]. Briefly, cell fluorescence was 
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continuously monitored at 488-nm excitation in open slide flow-loading
chambers mounted on the stage of a confocal Bio-Rad MRC-1024 ES
scanning microscope. The time course analysis of Ca2+ waves after cell
stimulation with 1.0 µM A42 aggregates was performed using the Time
Course Kinetics software (Bio-Rad). A single coverslip with adherent cells
was used for each experiment and a variable number of cells ranging from
10 to 22 were analysed. Fluorescence signals are expressed as average of
fractional changes in all cells above the resting baseline, F/F, as reported
above. Moreover, intracellular free Ca2+ was imaged in cells exposed for 
20 min. to A42 aggregates either in Ca2+-containing and in Ca2+-free
media, the latter including 5mM Mg2+ and 10 mM Ethylene Glycol-bis 
(-Aminoethyl ether)N,N,N’,N’-TeTraaceTic Acid (EGTA), according to
Demuro [39]. Then the cells were incubated with 10 µM Fluo3-AM for 
10 min., fixed with 2.0% paraformaldehyde for 10 min., mounted on
glass and analysed on the confocal microscope. In order to assess
whether A42 aggregates alter the membrane permeability, 22 treated
and control cells were loaded with 2.0 µM calcein for 30 min. and then
exposed to 1.0 µM A42 aggregates for 20 min.
Amyloid cytotoxicity assay
The effect of aggregate treatments on neuroblastoma cell morphology was
investigated by Hoechst 33342 dye staining. Briefly, after the exposure to
1.0 µM A42 aggregates for 24 hrs at 37°C, cells were incubated with
20µg/ml Hoechst for 15 min. at 37°C. Then, cells were fixed as above
reported. Blue fluorescence micrographs of cells were obtained under UV
illumination in an epifluorescence inverted microscope (Nikon, Diaphot
TMD-EF) with an appropriate filter set. Moreover, aggregate cytotoxicity to
neuroblastoma cells was assessed in 96-well plates by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as
previously reported [32]. Briefly, after the exposure to 1.0 µM A42, A40
or amylin aggregates for 24 hrs at 37°C, the cell cultures were incubated
with 0.5 mg/ml MTT solution at 37°C for 4 hrs and with cell lysis buffer
(20% SDS, 50% N,N-dimethylformamide, pH 4.7) overnight. Absorbance
values of blue formazan were determined at 590 nm. Cell viability was
expressed as percent of MTT reduction in treated cells as compared to
cognate untreated cells, where it was assumed as 100%. 
Statistical analysis
All data are expressed as mean  standard deviation (SD). Comparisons
between the different groups were performed by ANOVA followed by
Bonferroni’s t-test. A P-value less than 0.05 was accepted as statistically
significant.
Results
Modulation of cholesterol content 
in cellular compartments of human 
SH-SY5Y neuroblastoma cells
In the CNS, cell cholesterol is almost entirely provided by de novo
synthesis; accordingly, any modulation of the expression or activity
of the enzymes involved in cholesterol biosynthesis can rationally
produce a variation of its intracellular levels. In our experimental
model we modulated the activity of seladin-1, the enzyme that
catalyses the last step of cholesterol synthesis, by transiently over-
expressing its encoding gene or by the selective inhibition of its
enzymatic activity and evaluated the effect on total and membrane
cell cholesterol. The transient transfection of seladin-1 in SH-SY5Y
cells resulted in a significant increase in cell cholesterol after 
48 hrs. The increase was in the 10–20% range versus control for
total cell cholesterol and in the 30–60% range versus control for
membrane cholesterol, depending on transfection efficiency 
(Fig. 1). Conversely, SH-SY5Y cells were treated with 10 µM 22
for 48 hrs to specifically inhibit the enzymatic activity of seladin-1.
This treatment significantly reduced total and membrane cell cho-
lesterol by 10% and 15% versus control, respectively (Fig. 1). The
time dependent accumulation of the substrate desmosterol in 22-
treated cells indicates the selectivity of the inhibitor (Fig. 2A). Cell
treatment with the inhibitor and its effect on cell desmosterol con-
tent do not affect cell viability as assessed by the MTT assay 
(Fig. 2B). In another set of experiments carried out by incubating
human neuroblastoma cells in the presence of either PEG-choles-
terol or -CD we got similar modifications of membrane choles-
terol content independently from seladin-1 modulation (Fig. 1).
Increasing cell cholesterol reduces A aggregate
interaction with the cell membrane 
Cell degeneration in amyloid diseases appears mediated by a
toxic mechanism involving some interaction of the aggregated
species with the plasma membrane of the affected cells [30,
37–39]. In seladin-1 overexpressing cells and in PEG-cholesterol
supplemented cells the increase of plasma membrane choles-
terol resulted in a reduced A oligomer binding to the plasma
membrane respect to control cells. This is shown by confocal
microscopy analysis at different focal lengths of neuroblastoma
cells exposed for 10, 20, 30 and 60 min. to A42 pre-fibrillar
aggregates (Fig. 3A). Conversely, the same amyloid oligomers
added to the cell culture medium appear to accumulate more
quickly and to a greater extent at the plasma membrane in 22
and -CD treated cells characterized by a reduced content of
cholesterol than in control cells (Fig. 3A). The presence of amy-
loid aggregates bound to the plasma membrane of exposed cells
was detected by immunofluorescence using monoclonal anti-A
antibodies after cell membrane permeabilization with glycerol.
Notably, the red fluorescence signals related to 6E10 antibody,
that recognizes also the full length human APP, are negligible in
all the analysed conditions before A treatment (see time 0).
This evidence let us to rule out the possibility that the differences
in the accumulation of exogenous A at the cell membrane were
due to different levels of APP expression in these cells. The
analysis of SH-SY5Y neuroblastoma cells transfected with an
empty expression plasmid without the seladin-1 encoding gene
and of ethanol-exposed cells confirmed the specificities of the
recorded fluorescence signals (Fig. 3B). This evidence agrees
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with the Congo Red assay showing that seladin-1 overexpres-
sion and cell media supplementation with soluble cholesterol
resulted in a significant reduction of rate and extent of A42
aggregate binding to the cell plasma membranes respect to con-
trols (Fig. 3C). Conversely, the loss of membrane cholesterol
resulted in a higher rate of aggregate binding to the surface of
SH-SY5Y cells treated with the specific seladin-1 inhibitor 22
or with -CD as compared to control cultures. Finally, the ability
of exposed cells to bind A aggregates appeared saturable,
reaching its limit in the first 10–30 min. (Fig. 3C). No significant
difference in Congo Red absorbance values between different
groups of A42-untreated cells was observed. Seladin-1 has
been shown to affect plasmin activity [29] that is involved in A
degradation [20]. Therefore, we measured plasmin activity in
lysates of control cells, seladin-1 overexpressing cells and 22
treated cells. As shown in Figure 4, transient transfection of
seladin-1 in SH-SY5Y resulted in a significantly higher plasmin
activity than in control cultures. Conversely, loss in membrane
cholesterol resulting from cell treatment with 22, led to a sig-
nificant reduction of plasmin activity respect to control cells. The
variation of plasmin activity respect to control is greater for
seladin-1 overexpressing cells than for 22 treated cells. This
effect, as described by Crameri et al. [29], is likely ascribable to
the enhanced ability of cholesterol rich membranes to bind plas-
minogen. Having assessed the link between seladin-1 expres-
sion, membrane cholesterol levels and A aggregate interaction
Fig. 1 Modulation of total and membrane cholesterol in human SH-
SY5Y neuroblastoma cells. (A) Total cholesterol and (B) membrane
cholesterol in SH-SY5Y neuroblastoma cells 48 hrs after the transient
transfection of seladin-1, 1 hr after incubation with 0.1 mM PEG-chol,
48 hrs after the selective inhibition of the enzyme with 10 µM 22 and
30 min. after cell culture supplementation with 1mM -CD. The
amount of cholesterol was determined by gas chromatography-mass
spectrometry (GC-MS) using stigmasterol as internal standard as
specified under Materials and Methods. The reported values are repre-
sentative of three independent experiments. *Significant difference
(P0.05) versus control cells.
Fig. 2 22 inhibits seladin-1 enzymatic activity. (A) Desmosterol accu-
mulation during the treatment of SH-SY5Y cells with 10 µM 22 meas-
ured in total cell lysates. (B) MTT assay on SH-SY5Y treated for 24 and
48 hrs with 10 µM 22.
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Fig. 3 Increasing cell cholesterol reduces amyloid- peptide (A) aggregate interaction with the cell membrane. (A, B) Representative confo-
cal microscopy images showing aggregates in contact with, and penetrating into, the plasma membrane of neuroblastoma cells under different
experimental conditions. Cells transfected with empty expression plasmid without seladin-1 gene (C Sel) and cells exposed to ethanol (C 22)
were used as internal controls. After treatment for 0, 10, 20, 30 and 60 min. with A42 pre-fibrillar aggregates, counterstaining was performed
with fluorescein-conjugated wheat germ agglutinin to detect plasma membrane profile (green). The aggregates were labelled with monoclonal
mouse 6E10 anti-A antibodies and Texas Red-conjugated anti-mouse secondary antibodies with plasma membrane permeabilization with 
glycerol, as specified under Materials and methods. (C) Time-course of amyloid aggregate binding to neuroblastoma cells. After the exposure
to 1.0 µM A42 pre-fibrillar aggregates for 5, 10, 20, 30, 60 min., cells were washed twice with PBS and the residual aggregate-cell complex
was stained with 1.0 µM Congo Red for 20 min. Under these conditions, Congo Red-staining is a measure of the amount of 
pre-fibrillar aggregates adsorbed to cell membrane surface. *Significant difference (P  0.05) versus control cells. 
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with the plasma membrane of exposed cells, we sought to 
investigate whether the modulation of seladin-1 expression was
associated with any modification of plasma membrane perme-
ability to the external Ca2+ ions.
Seladin-1 protects against 
alteration of intracellular Ca2+ levels 
in cells exposed to A aggregates
Derangement of ion distribution across the plasma membrane is a
shared and early biochemical modification displayed by cells
exposed to toxic amyloid aggregates [32, 39, 40]. To investigate
Ca2+ homeostasis in our cell systems, we performed a confocal
microscopy time course analysis of the intracellular Ca2+ content
in unfixed viable differently treated SH-SY5Y cells plated on glass
coverslips upon exposure to A42 aggregates. A higher mem-
brane cholesterol content prevented the early and sharp increase
in cytosolic free Ca2+ levels induced by A aggregates in control
cells with basal cholesterol content (Fig. 5A). Actually, both in
seladin-1 overexpressing cells and in PEG-cholesterol treated cells
the content of cytosolic Ca2+ was substantially the same as that
found in cells not exposed to the aggregates and significantly
lower than in aggregate-exposed control cultures (Fig. 5C).
Similar experiments carried out on SH-SY5Y cells transfected with
an empty expression plasmid without the seladin-1 encoding gene
or on ethanol-exposed cells confirmed the specificities of the flu-
orescence signals (Fig. 5B). Conversely, loss in membrane choles-
terol, resulting from cell treatment with 22 or -CD, triggered an
accelerated and greater increase of cytosolic free Ca2+ (Fig. 5C).
Notably, no fluorescence signal decay was observed in the low
membrane cholesterol cells during the 20 min. continuous analy-
sis. Moreover, A aggregates failed to induce any modification of
the calcein signal in low cholesterol membranes from 22-treated
cells such as in control cells (Fig. 6A). Furthermore, to discrimi-
nate whether the increase in cytosolic Ca2+ concentration evoked
by A aggregates arose from the influx of extracellular Ca2+
across the plasma membrane or from Ca2+ release from the intra-
cellular stores, we conduced matching experiments on cells cul-
tured in Ca2+-free medium. The increase in Ca2+ fluorescence sig-
nal observed in cells exposed to A aggregates in Ca2+-containing
media was completely abolished when the cells were cultured in a
Ca2+-free medium (Fig. 6B). Next, we investigated whether mem-
brane cholesterol modulation following regulation of seladin-1
expression also resulted in modifications of A aggregate toxicity
to exposed cells.
High membrane cholesterol prevents 
A aggregate cytotoxicity 
To assess the effect of the regulation of membrane-cholesterol
homeostasis on amyloid toxicity, we evaluated the effect of our
treatments both on cell morphology and on the mitochondrial
status. As shown in Figure 7A, morphological evaluation of SH-
SY5Y cells using Hoechst 33342 staining revealed no marked
characteristics of apoptosis in cells overexpressing seladin-1 or
treated with PEG-cholesterol after their exposure to A aggre-
gates for 24 hrs respect to similarly exposed control cells with
basal cholesterol content. Accordingly, as revealed by the MTT
assay reported in Figure 7B, cells overexpressing seladin-1 or
treated with PEG-cholesterol exposed to A42 aggregates dis-
played significantly improved viability respect to similarly
exposed control cells with basal cholesterol content. Conversely,
loss in membrane cholesterol following cell treatment with 22
or -CD resulted in a significant increase in the number of cells
showing nuclear condensation (Fig. 7A) and in a significant
impairment of cell viability (Fig. 7B) upon exposure to the aggre-
gates, respect to similarly exposed control cells with basal cho-
lesterol content. Finally, the selectivity of the cytoprotective role
of seladin-1 was investigated in cells exposed to aggregates
other than A42, such as A40 and amylin (Fig. 7C). A reduced
susceptibility to the stress induced by A40 was observed in
seladin-1 overexpressing cells respect to control cells with basal
cholesterol content, confirming the increased resistance of these
cells. Reduced vulnerability was also seen when the same 
cells were exposed to amylin oligomers, further supporting the
generality of these effects. On the other hand, an increased vul-
nerability, though to a different extent, to both A40 and amylin
aggregates, was observed in 22-treated cells. 
Fig. 4 Seladin-1 modulation affects plasmin activity. Plasmin activity,
was assayed using the chromogenic substrate S-2251 in total lysates
from SH-SY5Y control cells, from cells 48 hrs after the transient trans-
fection of seladin-1 and from cells 48 hrs after the selective inhibition
of the enzyme with 10 µM 22. For details, see under Materials and
methods. 
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Fig. 5 Intracellular free Ca2+ levels in neuroblastoma cells exposed to A aggregates. A, Continuous confocal microscopy analysis of intracellular free
Ca2+ levels in neuroblastoma cells during the first 20 min. of exposure to A42 pre-fibrillar aggregates. Cytosolic Ca2+ levels were imaged by confo-
cal microscopy using the fluorescent dye Fluo-3AM as a probe, according to the method described under Materials and methods. (B) Changes in
intracellular free Ca2+ levels in empty expression plasmid without seladin-1 gene (C Sel) and cells exposed to ethanol (C 22). (C) A variable num-
ber of representative living cells ranging from 10 to 22 were analysed in each coverslip in three independent experiments. Fluorescence signals are
expressed as average of fractional changes in all cells above the resting baseline, F/F, where F is the average baseline fluorescence before the appli-
cation of the amyloid aggregates and F is the fluorescence change over the baseline. Values are expressed as % versus untreated cells. *Significant
difference (P0.05) versus control cells.
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Discussion
The possible relation between cholesterol and neurodegeneration
has recently led to focus on the role played by seladin-1, a flavo-
protein with desmosterol reductase activity that catalyses the last
step of cholesterol synthesis. Seladin-1 appears to be down-regu-
lated in brain areas more severely affected by AD and its overex-
pression increases the resistance against A-induced neurode-
generation [24, 28]. Moreover, reduced brain cholesterol, desmos-
terol accumulation, displacement of BACE1 from DRM light frac-
tions to APP containing fractions with increased APP  cleavage
and A production have been reported in seladin-1 gene knockout
mice respect to wild-type mice; conversely, seladin-1 overexpres-
sion in SH-SY5Y cells increases cell membrane cholesterol
favouring BACE1 recruitment into APP-devoid DRM fractions and
reducing both APP processing and A peptide production [29].
These data strongly support the involvement of seladin-1 in the
pathway of A production, however they do not address the pos-
sibility that cholesterol variations resulting from seladin-1 modu-
lation can affect directly cell resistance to A toxicity.
In the present study, we investigated whether the modulation
of membrane cholesterol by seladin-1 overexpression or inhibition
could influence A42 aggregate cytotoxicity to human neurotypic
SH-SY5Y cells by modulating A aggregate binding to the cell
membrane, in most cases a recognized key step in amyloid cyto-
toxicity, and membrane permeability to the external Ca2+. We
found that the levels of both the total and the plasma membrane
cholesterol were significantly higher in seladin-1 overexpressing
cells than in control cells, in agreement with previous data [29].
Conversely, inhibiting the enzymatic activity of seladin-1 resulted
in a significant reduction of total and membrane cell cholesterol.
As far as we know, this is the first time that a reduction of the
enzymatic activity of seladin-1 is correlated to a decrease of mem-
brane cholesterol and an increase of cell vulnerability to aggregate
toxicity. In spite of the limitation of the cell model used, this find-
ing supports the idea that the low seladin-1 levels found in AD
brains [24] are responsible for either the reduction of membrane
cholesterol described in those brains [21] and the increase of the
neuronal vulnerability to A aggregates.
Our data show that neuroblastoma cells enriched in membrane
cholesterol following overexpression of seladin-1 or treatment
with PEG-cholesterol display higher resistance to A42 aggregate
toxicity, in agreement with previous data on human neuroglioma
H4 cells and FNC-B4 cells [24, 28]. Conversely, reducing choles-
terol levels by seladin-1 inhibition or by cell treatment with -CD
resulted in increased cell vulnerability to A aggregates. Our evi-
dence suggests that seladin-1 is able to modulate plasmin activity
that is enhanced in seladin-1 overexpressing cells and reduced,
although to a lesser extent, in 22 treated cells. This effect, as
described by Crameri et al. [29], is probably ascribable to the
enhanced ability of cholesterol rich membranes to bind plasmino-
gen. Therefore the seladin-1-induced variation in membrane cho-
lesterol modulates A42 toxicity at least through two different
mechanisms: the modification of membrane permeability and the
modulation of plasmin activity. These two mechanisms appear to
affect in a different way cell susceptibility to A peptides. In par-
ticular, the change in membrane permeability induced by 22 cell
treatment is likely the predominant effect, while both two mecha-
nisms can equally contribute to cell protection when seladin-1 is
overexpressed. However, when seladin-1 is overexpressed, other
accessory effects of this multifunctional protein associated to its
ability to reduce caspase 3 activity [41, 42] and to control the
Fig. 6 A aggregates induce a rise in intracellular Ca2+ by affecting
membrane permeability. (A) Representative confocal microscopy
images of 22 treated cells loaded with calcein-AM and exposed or not
to A aggregates. (B) Confocal microscopy analysis of intracellular
free Ca2+ in fixed neuroblastoma cells exposed for 20 min. to A42
aggregates either in Ca2+-containing (+ Ca2+) and in Ca2+-free (	Ca2+)
medium. For details see under Materials and methods.
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Ras/p53 signalling pathway [43] cannot be excluded. On the other
hand our data indicate that, at least in our system, a reduction of
seladin-1 enzymatic activity with no modification of the total
amount of the protein, is sufficient to increase cell vulnerability by
lowering membrane cholesterol. Overall, our data and those pre-
viously reported suggest that the higher vulnerability to A aggre-
gates of the AD relevant brain areas where seladin-1 is down-reg-
ulated results, at least in part, from the decrease of its enzymatic
activity and hence of the content of cholesterol in the neuronal
membranes. It is worth noting that this effect is unlikely to result
from the build-up of the seladin-1 substrate desmosterol in
seladin-1 deficient cells; in fact it has previously been reported
that the increase of desmosterol in cultured cells does not affect
DMR structure and function [29]. Moreover, our data show that
the treatment with 22 did not affect cell viability. Conversely, the
protective effect demonstrated in cells overexpressing seladin-1
Fig. 7 Seladin-1 protects against A
aggregate toxicity. (A) The effect of
A42 aggregates on neuroblastoma 
cell morphology was evaluated using
the Hoechst 33342 dye staining.
Representative blue fluorescence micro-
graphs of untreated (–A42) or exposed
SH-SY5Y cells to A42 aggregates for
24 hrs (+A42). For details, see under
Materials and methods. (B) Membrane
cholesterol enrichment by seladin-1
overexpression or PEG-cholesterol
treatment protects neuroblastoma cells
against amyloid aggregate toxicity. Cell
viability was checked by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) reduction test in
cells treated with 1.0 µM A42 pre-fib-
rillar aggregates for 24 hrs. The reported
values are representative of four inde-
pendent experiments, each performed in
triplicate. (C) Cell viability was also
checked by the MTT reduction test in
control cells, seladin-1 overexpressing
cells and 22 treated cells exposed to
1.0M 40 and amylin pre-fibrillar
aggregates for 24 hrs. The reported val-
ues are representative of three inde-
pendent experiments, each performed in
triplicate.*Significant difference
(P0,05) versus control cells.
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should correspond to a decrease in cell desmosterol for the
enhancement of seladin-1 enzymatic activity. The final effect of
cholesterol-desmosterol modulation on cell susceptibility to A42
peptides is similar to that obtained with -CD or PEG-Chol as
assessed by the MTT assay. These latter treatments did not affect
cell desmosterol only modulating cell cholesterol. These data,
although indirectly, support our opinion that cholesterol modula-
tion and not desmosterol modification is responsible of this final
effect. Remarkably, A40 and amylin treatments of seladin-1 over-
expressing or 22 inhibited cells affect cell viability resembling
A42 outcome. These data suggest that the seladin-1-dependent
modification of membrane cholesterol is generally able to modu-
late the toxic effect of amyloidogenic peptides independently from
their amino acid sequence. 
We previously reported that amyloid cytotoxicity can be
related, among others, to the ability of the aggregates to interact
with the plasma membrane [32]; in addition, disruption of cho-
lesterol homeostasis can be detrimental to cells because toxic
A aggregates interact more easily with cholesterol-depleted
membranes [16, 17]. Therefore, we investigated whether mem-
brane content of cholesterol could affect the rate and extent of
A42 aggregate interaction with the plasma membrane of our
neuronal cell model. We found by confocal microscopy and
Congo red assay that the binding rate of the A42 assemblies to
the plasma membranes of A42-exposed cells was significantly
faster and increased in cholesterol-poor cells treated with 22
and -CD than in cholesterol-enriched cells overexpressing
seladin-1 or treated with PEG-cholesterol. These findings con-
firm previous results [32] and the idea that the ability of A42
aggregates to bind to the plasma membrane is significantly
affected by its content in cholesterol. In particular, our data agree
with several reports indicating that cholesterol content affects
membrane physical features, such as fluidity and density of lipid
packing resulting in alterations of aggregate recruitment to the
membrane and membrane permeabilization [17]. Under our
experimental conditions, the differences found between 22-
and -CD-treated cells in A binding to the cell membrane and
in the intracellular calcium spikes cannot be explained by a sig-
nificant variation in cholesterol membrane content. An in depth
investigation of membrane distribution of cholesterol in 22-
and -CD-treated cells appear useful to substantiate this differ-
ent behaviour. It has previously been reported that A binding
and aggregation occurs in the lipid raft and is mediated by clus-
ters of the ganglioside GM1, as detected by ThT or Congo Red
[44]. It was hypothesized that A adopts an altered conforma-
tion through its binding to GM1 acting as a seed for A fibrillo-
genesis in AD brain [44]. It has also been reported that GM1
clusters are susceptible to membrane cholesterol depletion [45].
Recent evidence suggests that A interacts with the APP pres-
ent at the cell surface and acts as a ligand of its own precursor,
resulting in a cell death-related signal [46]. We cannot exclude
that different APP distribution and/or accessibility in the plasma
membranes, likely resulting from lipid raft reorganization at our
different experimental conditions, may contribute to the interac-
tion of the A aggregates with the cell membranes.
It has previously been shown that enriching with cholesterol
the plasma membranes of PC12, SH-SY5Y and GT1-7 cells modi-
fies membrane fluidity preventing A incorporation into, and per-
meabilization of, the cell membrane [16, 17, 31]. A leading theory
on the molecular basis of amyloid toxicity is that pore-like pre-fib-
rillar aggregates interact with the cell membranes leading to mem-
brane permeabilization and free Ca2+ imbalance [37, 47–51]. Our
confocal images show that in our exposed cells an early, sharp
increase of free cytosolic Ca2+ does occur, in agreement with pre-
viously reported findings [40]. Actually, our cholesterol-poor cells
displayed a prompt and enhanced Ca2+ increase upon aggregate
binding to the cell membrane respect to control cells whereas cho-
lesterol-enriched cells displayed slower and reduced A aggregate
binding to the plasma membrane resulting in a delayed and signif-
icantly reduced rise of free Ca2+ content respect to control cells.
The Ca2+ signals evoked by A42 oligomers were abolished in
cells cultured in Ca2+-free medium, indicating a main contribution
from extracellular, rather than from the intracellular, Ca2+ sources.
We also sought to provide information on weather intracellular
free Ca2+ dyshomeostasis in seladin-1 down-regulated neurons of
AD-affected brain areas could result from a generalized increase in
membrane permeability [39, 52] or from the formation of mem-
brane pores [30, 49–51]. In our cell model, we did not observe
any rapid fluorescence signal decay in low membrane cholesterol
cells, suggesting the absence of a fluorescent dye leakage invoked
by a generalized increase in membrane permeability induced by
A aggregates. On the contrary, our calcein data suggest a selec-
tive-specific pore-like mechanism for oligomer-mediated toxicity,
even though minor changes of membrane permeability cannot be
ruled out. The relevance of these finding is stressed by the well
known association between alterations of intracellular free Ca2+
and either oxidative stress [53] and cell death [54].
Overall, our results provide information useful to depict a
mechanism of cell impairment and death that can be common to
pre-fibrillar aggregates of most peptides and proteins. It apparently
starts with aggregate binding to the cell membrane resulting in
membrane permeabilization, subsequent alteration of ion distribu-
tion inside exposed cells and oxidative stress [32, 55]. Seladin-1
down-regulation or inhibition can contribute to such a chain of
events, indicating the importance, among the different activities of
seladin-1, of its regulatory effect on membrane cholesterol levels.
Conversely, seladin-1 overexpression and the resulting membrane
cholesterol increase provide a mechanistic explanation of the
cytoprotection by seladin-1 against aggregate toxicity. Our data,
together with many others, suggest that neuronal integrity
requires the maintenance of a proper steady-state level of brain
cholesterol and that its reduction, even a moderate one such as
that obtained by seladin-1 inhibition or by -CD treatment, results
in severe impairment of cell viability. These results implement the
recently published data on the role of a moderate reduction of
membrane cholesterol in AD pathogenesis [12]. In particular, they
suggest that a mild loss of neuronal membrane cholesterol results
not only in altered APP processing with increased A production
[15, 29] but also in a quicker and increased binding of secreted A
oligomers to the neuronal membrane with subsequent alteration
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of Ca2+ distribution and cell damage. The recently reported
seladin-1 down-regulation in AD patients is likely to contribute to
this mechanism by a reduced cholesterol synthesis. Taken
together these and other recently reported data highlight Seladin-
1/DHCR24 as a possible new susceptibility gene and pharmaco-
logical target for sporadic AD. Further investigation is needed to
confirm such possibility.
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